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Clinical Update
gical DMARDs. Most people who develop RA today
have their disease well c ntrolled and are likely to
long-term damage and disability. In most cases, 
continue medication is lifelong, as RA will genera
medication withdrawal.21
Despite the evidence of DMARD effectiveness, bar
mentation remain. The way forward may require bro122 MJA • Volume 184 NumbABSTRACT
• Most people presenting with rheumatoid arthritis today can 
expect to achieve disease suppression, can avoid or 
substantially delay joint damage and deformities, and can 
maintain a good quality of life.
• Optimal management requires early diagnosis and treatment, 
usually with combinations of conventional disease modifying 
antirheumatic drugs (DMARDs). If these do not effect 
remission, biological DMARDs may be beneficial.
• Lack of recognition of the early signs of rheumatoid arthritis, 
ignorance of the benefits of early application of modern 
treatment regimens, and avoidable delays in securing 
specialist appointments may hinder achievement of best 
outcomes for many patients.
• Triage for recognising possible early rheumatoid arthritis 
must begin in primary care settings with the following pattern 
of presentation as a guide:
¾ involvement of three or more joints;
¾ early-morning joint stiffness of greater than 30 minutes; or
¾ bilateral squeeze tenderness at metacarpophalangeal or 
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metatarsophalangeal joints.he
thi
peR umatoid arthritis (RA) affects 1% of the population, two-rds of whom will develop erosive joint disease, and has aak incidence at 20–40 years of age. After 10 years of
disease, 50% of people with RA are unable to work because of
disability. Mortality rates are also increased, with RA patients’
average life expectancy being reduced by 10 years. The major cause
of this premature death appears to be accelerated atherosclerosis.1
Over the past 10 years, the traditional nihilistic view of RA
treatment has been replaced by an evidence-based “attitude” of
therapeutic opportunity.2 This change has been achieved through
the use of the class of medications known as disease modifying
antirheumatic drugs (DMARDs; Box 1) and is the result of three
major advances: early use of DMARDs, use of DMARDs in
combination, and the advent of new DMARDs, including biolo-






ation (among both primary care physicians and the public) of the
benefits of the revolution in treatment in RA and logistic changes
in the way specialist rheumatologists and arthritis clinics triage
appointments. These barriers to implementation have been high-
lighted by the Australian National Health Priority for Arthritis and
Musculoskeletal Conditions as a priority issue (NHPAC Action
Plan for Arthritis).
Levels of evidence in the following review are derived from the
National Health and Medical Research Council’s system for assess-
ing evidence.22
Methotrexate and disease modification (E1)
Methotrexate has become the first-line treatment for all but the
mildest RA, and is the standard against which other treatments are
compared. As an example of its ascendancy, in one academic
rheumatology setting in 1985 only 10% of RA patients were taking
methotrexate, compared with 76% in 2000.23 As monotherapy,
methotrexate reduces disease activity and the rate of joint erosions
(E1).3 In addition, methotrexate has been associated with a substan-
tial reduction in long-term mortality in RA patients. This survival
benefit was not provided by sulfasalazine, hydroxychloroquine, gold
or penicillamine (E3-2).24 The safety profile of low dose weekly
methotrexate is entirely acceptable compared with other options
(Box 1), based on experience with its widespread use since the mid
1980s. Concerns regarding progressive liver damage as a conse-
quence of weekly low dose methotrexate have not been realised, and
most patients continue on methotrexate for many years, providing
further evidence of its favourable risk–benefit profile.25
Early DMARD use (E2)
Although there have been proponents of early DMARD use for
many years, withholding DMARDs until radiographic joint ero-
sions had occurred was considered reasonable as recently as 12
years ago.26 The current widespread acceptance of an early
DMARD approach2 has been driven by complementary streams of
evidence. First, joint damage occurs early in the disease process.
Seventy-five per cent of joint erosions occur within the first 2
years, and at least 25% of patients already have erosions at disease
diagnosis.27 Second, early DMARD use decreases rates of joint
damage compared with delayed DMARD use.2 Delays of even a
few months in commencing DMARD treatment may result in a
more aggressive disease course in the first year.28 Third, early
DMARD use appears to make the disease easier to control in the
long term (Box 2).29 Last, DMARD treatment is remarkably safe
when used correctly.25er 3 • 6 February 2005
CLINICAL UPDATECurrent recommendations suggest commencing DMARD treat-
ment at the time of RA diagnosis.2 Although diagnostic certainty is
more difficult to achieve in early RA than in more established
disease, the safety of treatment justifies early DMARD treatment,
and early diagnosis is usually achievable in specialist early arthritis
clinics or community-based rheumatology settings. As more than
90% of patients with recent onset polyarthritis of more than 12
weeks’ duration can be expected to progress to established RA,30
almost everyone treated with DMARDs at that stage can be
expected to benefit.
Of more practical concern is the sometimes difficult distinction
between early RA and non-threatening chronic rheumatic condi-
tions. The synovitis that is usually present in early RA is a critical
discriminator, but non-specialists may not reliably detect it,31
highlighting the need for referral if there is any doubt. Fortunately,
recent developments may increase diagnostic confidence in early
disease. New diagnostic guidelines for early RA that determine the
likelihood of persistence and erosiveness are being validated.32 In
specialist clinical settings, magnetic resonance imaging and ultra-
sonography can confirm the presence of joint synovitis when there
is clinical uncertainty, and detect joint erosions well before they are
visible on radiographs.33 Antibodies against cyclic citrullinated
peptide appear to be specific for RA, with a high positive predictive
value.34 In future, novel biomarkers are likely to provide addi-
tional diagnostic and prognostic certainty, and may allow targeting
of specific DMARD treatments to individuals.32
Combination DMARD use with methotrexate (E2)
Different combinations of DMARD treatments have been studied
in randomised controlled trials (Box 1).2 Generally, these trials
have included patients with ongoing disease activity despite
adequate methotrexate treatment. The message from these trials is
that patients who do not respond to DMARD monotherapy are
likely to respond to the addition of a second and sometimes a third
DMARD, or so-called step-up therapy. This is a
change from previous practice, in which DMARDs
were substituted sequentially (ie, serial mono-
therapy). Furthermore, there is evidence that com-
bination DMARD therapy from the outset is superior
to DMARD monotherapy in inducing remission and
preventing joint damage.35 Although the specific
details of the best DMARD protocol remain to be
elucidated and must often be tailored to the individ-
ual, early combination DMARD therapy in active RA
is the most effective strategy for disease suppression
and containment of joint damage (E2).
Perhaps surprisingly, the tolerability and toxicity
of combination treatment was no different from that
of monotherapy in these short-term trials. One
caveat is that randomised controlled trials are not
able to accurately measure the rate of “serious but
rare” side effects because of their small sample size.
In addition, the long-term risks of combination
DMARD therapy in RA are not known. On the other
hand, the long-term risks of uncontrolled RA are
substantial. The balance of these benefits and risks
has lead to recommendations to implement com-
bination DMARD treatment in early active RA.2
New DMARDs
In the past decade, cyclosporin, leflunomide, and the biological
DMARDs, including the tumour necrosis factor (TNF) inhibitors
infliximab, etanercept, and adalimumab, and the interleukin 1
receptor inhibitor anakinra, have become available in Australia for
the treatment of RA. These agents differ in effectiveness and risk
(Box 1). Used as monotherapy, and more especially when used in
combination with methotrexate, the TNF inhibitors have added
substantially to the range of effective agents for RA.
Individual tolerance and response to all available agents varies.
Treatment plans need to be guided by (i) dosage adjustments
according to objective response criteria, (ii) disease remission as
the treatment goal, (iii) monitoring for known and emergent
2 Potential average effect of early or late disease 
modifying antirheumatic drug treatment on the 
activity of rheumatoid arthritis over time
Early treatment appears to improve remission rates.29 Shaded area under the 
curve represents permanent joint damage that accrues during periods of 








1 Efficacy, safety and monitoring principles for disease modifying 












Methotrexate ++4 — + FBC, LFT
Sulfasalazine ++5 +++6,7 + FBC, LFT
Hydroxychloroquine +8 ++6 - Retinal examination
Leflunomide ++9 +++10 + FBC, LFT
Tumour necrosis 
factor inhibitors
++11 +++11-13 + FBC, E+C, LFT
Anakinra + ++14 + FBC, E+C, LFT
Intramuscular gold ++15 +++16 ++ FBC, Urinalysis
Cyclosporin ++17 +++18 ++ FBC, E+C, LFT, BP
Azathioprine +19 Unknown + FBC, LFT
Cyclophosphamide ++19 Not used +++ FBC, E+C, LFT, urinalysis
D-Penicillamine ++20 Unknown +++ FBC, E+C, LFT, urinalysis
+/– scoring is a clinical guide to relative effects representing the views of the authors based on 
published studies where indicated. +++ represents the maximum efficacy or toxicity. FBC = full 
blood count. LFT = liver function tests. E+C = electrolytes and creatinine. BP = blood pressure. ◆MJA • Volume 184 Number 3 • 6 February 2005 123
CLINICAL UPDATEintolerances, and (iv) cost. For example, the annual prescription
cost of methotrexate is of a similar order to the average daily cost
for a bDMARD.
Barriers to implementation of the evidence in early RA
The evidence outlined above provides solid support for early
diagnosis and combination DMARD therapy in RA. Meeting the
challenge of this evidence requires improvements in early recogni-
tion in primary care, improvements in systems to provide timely
evaluation of people with possible early RA, and orderly
approaches to management.
The clinical difficulty of early diagnosis
There are several reasons for difficulty in making an early dia-
gnosis. First, inflammatory arthritis is a common manifestation of
many conditions, some of which are generally benign and/or self-
limiting (eg, viral arthritis, osteoarthritis), while others are more
serious (eg, systemic vasculitis, infective endocarditis). However,
investigations such as viral screens at presentation, and special
investigations triggered by clinical suspicion are often helpful to
exclude other diagnoses. Second, the “classical” clinical pattern of
RA with persistent symmetrical small and large joint arthropathy
tends to emerge over time, with a migratory (“palindromic rheu-
matism”) or incomplete pattern often present in the first few
months or even years. Third, diagnostic criteria or tests that may
be useful in established disease, such as rheumatoid factor and
hand radiographs, are more likely to be negative in early disease.
As a diagnostic test for RA, rheumatoid factor is neither very
sensitive nor specific. The assay for cyclic citrullinated peptide
antibodies (anti-CCP) may be more informative.34 However, over-
reliance on negative results from these tests may delay referral,
diagnosis, and effective DMARD treatment. Fourth, symptoms and
signs may be masked by treatment with anti-inflammatory drugs
or corticosteroids.
Health system barriers
The limited Australian data on diagnostic and treatment delays in
early RA indicate problems in recognition and timely referral at the
primary care level, as well as delays between referral and first
specialist assessment. For example, at a large Melbourne public
hospital outpatient department in 2002, the median delay between
symptom onset and referral was more than 10 months, and the
median delay between referral and first specialist assessment was
almost 2 months.36 In contrast, a survey of community-based
rheumatologists in the same geographic area showed a delay of 3
months between symptom onset and referral, and 1 month
between referral and first specialist assessment.
Timeliness of access to specialist services will vary depending on
the location, and large variability is likely to exist between urban
and rural settings. Thus, a more systematic approach to triage and
referral may ensure that most patients with RA have rapid access to
best-practice treatment.
Overcoming the barriers
Timeliness of access to specialty assessment may deteriorate
further as consultant rheumatologists struggle to keep pace with
the burgeoning clinical demands of ageing and chronic arthritic
disease. This potential crisis may mandate triage systems which
focus specialist resources on clinical priorities, such as RA, where
treatment is complex, and the gap between outcomes from best
practice and non-expert interventions is greatest. This philosophy,
which has its antecedents in coronary care and emergency units,
has encouraged the establishment of Early Arthritis Clinics. These
clinics have successfully reduced delays in instituting DMARD
treatment in other countries by applying a structured triage
process, prompt specialist clinical assessment and diagnosis, pre-
determined default evidence-based treatment plans, and regular
communication links with primary care clinicians.31 With appro-
priate organisation, this manner of coordinated and structured
health care can be delivered by community-based rheumatologists.
These community-based services, which form the backbone of
rheumatology care, may be organised on a “standalone” basis or
through collaborations with pioneering teaching hospital-based
services. The more orderly management approaches inherent in
such services provide opportunities to delegate tasks to practice
nurses and assistants, thereby achieving economies without com-
promising care.37
Successful triage systems require an accurate clinical assessment
in the primary care setting. A simple system has been successfully
trialled in a community setting in England and is likely to be useful
in Australia (Box 3).38 In general, the following findings are
suggestive of early rheumatoid arthritis and warrant specialist
referral: recent onset of joint swelling, symmetrical symptoms,
metacarpophalangeal or metatarsophalangeal involvement, signifi-
cant early morning stiffness, a good response to non-steroidal anti-
inflammatory drugs, and a family history of rheumatoid arthritis.
Initial treatment with a non-steroidal anti-inflammatory agent can
provide symptomatic relief, which is of some diagnostic utility.
Glucocorticoid use is not encouraged. Glucocorticoids are such
potent anti-inflammatory and mood-altering agents that short-
term relief is nonspecific, their capacity to suppress joint swelling
and acute phase response adds to diagnostic difficulties, and their
use may deflect from or delay the application of more effective
DMARD therapy.
Conclusions
There have been important advances in the treatment of RA in the
past 10 years. Early treatment with combinations of DMARDs
provides the most effective disease control and prevention of long-
term joint damage. This strategy is also likely to result in
substantial downstream health cost savings as disability and
workforce-withdrawal are reduced. Newer DMARDs have
increased the therapeutic armamentarium such that for most
people with RA, a safe and effective treatment is available. In
addition to early arthritis clinics, improved triage systems are
3 Triage system for identification of possible early 
rheumatoid arthritis 38
Any positive findings in the following three features might warrant 
referral for early arthritis assessment:
• three or more swollen joints
• early morning joint stiffness > 30 minutes
• bilateral metatarsophalangeal or metacarpophalangeal squeeze 
tenderness
AND arthritis (pain) duration < 1 year ◆124 MJA • Volume 184 Number 3 • 6 February 2005
CLINICAL UPDATErequired to help the health system meet the challenge of universal
early diagnosis and treatment of RA.
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